Asston Pharmaceu

Why is Asston Pharmaceuticals Ltd falling/rising?

As of 14-Jul, the stock price of Asston Pharmaceuticals Ltd is at 75.00, unchanged from the previous day, and has underperformed its sector by 1.95%. The stock shows a trend reversal after five days of gains, with a 1.31% increase over the past week but a 9.40% decline over the past month, indicating reduced investor interest and a potential bearish trend.

As of 14-Jul, the stock price of Asston Pharmaceuticals Ltd is currently at 75.00, showing no change from the previous day. The stock has underperformed its sector by 1.95% today and has experienced a trend reversal, having fallen after five consecutive days of gains. Additionally, the stock's performance over the past week shows a modest increase of 1.31%, while it has declined by 9.40% over the past month. <BR><BR>Investor participation has also decreased, with delivery volume dropping by 43.18% compared to the five-day average, indicating reduced interest from investors. Furthermore, the stock is trading at the same price it opened, suggesting a lack of volatility or movement in the stock price. Although the stock is currently above its 5-day moving averages, it remains below the 20-day, 50-day, 100-day, and 200-day moving averages, which could indicate a bearish trend in the longer term. Overall, these factors contribute to the stock's current stagnation and potential decline.

Which are the latest news on Asston Pharmaceu?

What does Asston Pharmaceu do?

Asston Pharmaceuticals Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, with a market cap of INR 58 Cr. It has no reported sales or profits for the latest quarter, a P/E ratio of 16.00, and a debt-equity ratio of 0.10.

Overview: <BR>Asston Pharmaceuticals Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>The incorporation year and any status changes are not provided. There are no sales or profit figures reported for the latest quarter.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 58 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 16.00 <BR>Industry P/E: N/A <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.10 <BR>Return on Equity: 10.02% <BR>Price-to-Book: 1.54 <BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: Not available. <BR>Email: Not available. <BR>Website: Not available.

How big is Asston Pharmaceu?

As of 10th June, Asston Pharmaceuticals Ltd has a market capitalization of 58.00 Cr, classifying it as a Micro Cap company. There is no available financial data for Net Sales and Net Profit for the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Asston Pharmaceuticals Ltd has a market capitalization of 58.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales and Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The latest reporting period is March 2025, with Shareholder's Funds amounting to 11.04 Cr and Total Assets valued at 28.10 Cr.

Who are the peers of the Asston Pharmaceu?

Asston Pharmaceu's peers include Vineet Laborator, Sunil Healthcare, Samrat Pharma, and others, with varying management risks and growth rates. Kabra Drugs shows the highest 1-year return at 86.81%, while Samrat Pharma has the lowest at -41.51%.

Peers: The peers of Asston Pharmaceu are Vineet Laborator, Sunil Healthcare, Samrat Pharma, Biofil Chemicals, Vivo Bio Tech, Shelter Pharma, Kabra Drugs, Vasundhara Rasy., JFL Life, and Ajooni Biotech.<BR><BR>Quality Snapshot: Excellent management risk is observed at Kabra Drugs and Vasundhara Rasy., while Average management risk is found at Samrat Pharma, Shelter Pharma, and JFL Life, and the rest. Below Average management risk is present at Vineet Laborator, Sunil Healthcare, Biofil Chemicals, Vivo Bio Tech, and Ajooni Biotech. Growth is Excellent at Kabra Drugs and JFL Life, Good at Sunil Healthcare and Shelter Pharma, Average at Asston Pharmaceu and Ajooni Biotech, and Below Average at the rest. Capital Structure is Excellent at Samrat Pharma and Shelter Pharma, Good at Biofil Chemicals and Vasundhara Rasy., Average at Asston Pharmaceu, and Below Average at the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Kabra Drugs at 86.81%, while the lowest is Samrat Pharma at -41.51%. Asston Pharmaceu's 1-year return is not available for comparison. Additionally, the peers with negative six-month returns include Sunil Healthcare, Samrat Pharma, Vivo Bio Tech, Shelter Pharma, and Kabra Drugs.

When is the next results date for Asston Pharmaceuticals Ltd?

The next results date for Asston Pharmaceuticals Ltd is 29 May 2026.

The next results date for Asston Pharmaceuticals Ltd is scheduled for 29 May 2026.

Is Asston Pharmaceu overvalued or undervalued?

As of November 26, 2025, Asston Pharmaceu is considered overvalued with a PE ratio of 22.11, a price-to-book value of 2.20, and an EV to EBITDA ratio of 16.35, despite outperforming the Sensex with a 1-week return of 17.65%.

As of 26 November 2025, Asston Pharmaceu's valuation grade has moved from fair to expensive, indicating a shift towards overvaluation. The company is currently assessed as overvalued, with a price-to-earnings (PE) ratio of 22.11, a price-to-book value of 2.20, and an EV to EBITDA ratio of 16.35. These metrics suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Asston Pharmaceu's PE ratio is lower than that of Sun Pharma (37.53) and Divi's Lab (69.71), both categorized as expensive, while it is slightly higher than Cipla (22.59) and Dr. Reddy's Labs (18.02), which are viewed as attractive. The company's recent stock performance has outpaced the Sensex, with a 1-week return of 17.65% compared to the Sensex's 0.50%, reinforcing the notion of overvaluation in the current market context.

How has been the historical performance of Asston Pharmaceu?

Asston Pharmaceu experienced significant growth from March 2024 to March 2025, with net sales rising to 25.04 Cr from 15.59 Cr, and profit after tax increasing to 4.33 Cr from 1.36 Cr. Key metrics such as EPS improved to 6.91 and operating profit margin rose to 24.64%, indicating a strengthening financial position.

Answer:<BR>The historical performance of Asston Pharmaceu shows significant growth in various financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Asston Pharmaceu reported net sales of 25.04 Cr in March 2025, a notable increase from 15.59 Cr in March 2024. Total operating income also rose to 25.04 Cr from 15.59 Cr, driven by an increase in raw material costs to 14.13 Cr from 9.75 Cr. The total expenditure, excluding depreciation, increased to 18.87 Cr from 13.04 Cr, resulting in an operating profit (PBDIT) of 6.74 Cr, up from 2.80 Cr. Profit before tax surged to 5.70 Cr from 1.82 Cr, leading to a profit after tax of 4.33 Cr, compared to 1.36 Cr the previous year. The earnings per share (EPS) improved significantly to 6.91 from 2.18, while the operating profit margin increased to 24.64% from 16.36%. The total assets of the company grew to 28.10 Cr from 20.70 Cr, with total liabilities also rising to 28.10 Cr from 20.70 Cr. The book value per share adjusted increased to 17.6 from 11.45, reflecting the company's strengthening financial position.